Department of Urology

Medicine & Life Sciences

1. Renal Cell Carcinoma 100%
2. Prostatic Neoplasms 75%
3. Urinary Bladder Neoplasms 57%
4. Neoplasms 47%
5. Nephroureterectomy 43%
6. Carcinoma 43%
7. Castration 34%
8. Recurrence 31%
9. Prostate-Specific Antigen 28%
10. Survival 24%
11. Prostatectomy 23%
12. Kidney 23%
13. Neoplasm Metastasis 22%
14. Prostate 21%
15. Therapeutics 21%
16. Nephrectomy 17%
17. Japan 16%
18. cabazitaxel 15%
19. Axitinib 14%
20. Urinary Bladder 14%
21. Drug Therapy 13%
22. Adrenalectomy 13%
23. Androgens 13%
24. Sunitinib 12%
25. Cystectomy 12%
26. Nivolumab 11%
27. Docetaxel 11%
28. Cisplatin 11%
29. Urinary Tract 10%
30. Survival Rate 9%
31. Brachytherapy 9%
32. Bacillus 9%
33. Tomography 9%
34. Safety 9%
35. Sorafenib 9%
36. Angiomyolipoma 9%
37. Progression-Free Survival 9%
38. Multivariate Analysis 9%
39. Biopsy 8%
40. Neoplasm Grading 8%
41. Biomarkers 8%
42. dehydroxymethylepoxyquinomicin 8%
43. Platinum 7%
44. pembrolizumab 7%
45. Hydronephrosis 7%
46. Ureter 6%
47. Renal Dialysis 6%
48. Lymph Nodes 6%
49. Radiotherapy 6%
50. Genes 6%
51. Urologic Neoplasms 6%
52. Aldosterone 6%
53. Kidney Neoplasms 6%
54. Interleukin-2 6%
55. Ureteral Obstruction 6%
56. Apoptosis 5%
57. C-Reactive Protein 5%
58. Angiotensin Type 1 Receptor 5%
59. gemcitabine 5%
60. Molecular Targeted Therapy 5%
61. Lymph Node Excision 5%
62. Urologists 5%
63. Retrospective Studies 5%
64. Hematuria 5%
65. Serum 5%
66. Operative Time 5%
67. Magnetic Resonance Imaging 5%
68. Incidence 5%
69. Pneumoperitoneum 5%
70. Pheochromocytoma 5%
71. Prostatic Hyperplasia 5%
72. Lung 5%
73. Mutation 5%
74. Ultrasonography 5%
75. Urine 5%